sameAs
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsDiscovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and cPF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsResensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinibMechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and Cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyWe shall overcome (drug resistance) some dayLorlatinib: First Global ApprovalLorlatinib for the treatment of patients with non-small cell lung cancerLorlatinib effective in multiple settings
P921
Q27908390-B65D3828-5885-47CB-B5A4-9E421C1EB2A7Q27919341-941278E6-8ECC-47D3-8A0D-B922A7871BD8Q28370062-3B2FB196-9F92-4F4F-802A-4990D9D7FC98Q28370065-456BA50B-6921-4784-B64D-0F61A3FE7B4BQ28370067-870ED4B3-8F61-4A21-8146-E2A3EF1D1FC4Q28371428-F4C32D99-36F1-4028-B66F-274642D65ED6Q28371474-0A48ECBB-C74A-4685-824F-96959DEF18C1Q28371504-8ED4CA7C-33E2-40A1-A0A2-7F86E4FAC834Q96007988-B91583C0-C217-4AF4-B53D-1DCDA50E6643
P3354
Q26740329-D96A6A9F-B30E-4883-85EB-7EC83A903279Q27690215-7D0F7229-BCE8-48D6-BC04-4143296207FEQ27853138-75379B8E-6FB7-425F-9001-2FA9CBCAA922Q27853298-68DA1628-016D-497E-95F8-41875C70B8DEQ33804619-204E7970-7FB0-4047-B148-C1B1766E342BQ38944685-A8EE75D0-3B12-4258-A990-4277D56BC053Q38970574-51F5A8CD-3568-4A46-BDD5-26FF99E35283Q48904628-193BABD3-B6A3-49DD-8093-357C6B89FCA4Q54979413-49135C41-7EE1-4D18-9526-7609F9CE7962Q58607887-06906597-CDE2-41F0-A27E-D9B14F65BF22Q61806354-C223C9F1-9B98-43F7-98BE-AE7DFCADA11FQ90859313-C80B09D3-5199-4EDF-A23C-83F51D67F2A9Q92001448-91BB9BE1-4218-4E95-8E0A-4F9A6318F9A3Q93382097-FEF8D398-34CD-47C0-9C7E-AE35989DFD2A
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
lorlatinib
@en
ロルラチニブ
@ja
type
label
lorlatinib
@en
ロルラチニブ
@ja
altLabel
Lorlatinib
@en
PF-6463922
@en
prefLabel
lorlatinib
@en
ロルラチニブ
@ja
P592
P661
P662
P683
P117
P2017
C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
P2067
P231
1454846-35-5
P232
P233
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
P234
1S/C21H19FN6O2/c1-11-15-7-13(2 ...... H2,1-3H3,(H2,24,25)/t11-/m1/s1
P235
IIXWYSCJSQVBQM-LLVKDONJSA-N
P2566
100.245.079
P267
P274
C₂₁H₁₉FN₆O₂
P592
CHEMBL3286830
P652
OSP71S83EU
P661
P662
P683
P7830
Lorlatinib